[Federal Register Volume 63, Number 201 (Monday, October 19, 1998)]
[Notices]
[Pages 55886-55887]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-27961]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: 21 Substituted
Progesterone Derivatives as New Anti-Progestational Agents
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license worldwide to practice the invention embodied in:
U.S. Patent Application Serial No. 60/016, 628, filed May 1, 1996
entitled, ``21 Substituted Progesterone Derivatives as New Anti-
Progestational Agents'' to Zonagen, Inc., having a place of business in
Houston, TX. The patent rights in this invention have been assigned to
the United States of America.
DATES: Only written comments and/or application for a license which are
received by the NIH Office of Technology Transfer on or before December
18, 1998 will be considered.
ADDRESSES: Requests for a copy of the patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Dennis H. Penn, Pharm.D., Technology Licensing
Specialist, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 496-7056, ext. 211; Facsimile: (301) 402-0220.
SUPPLEMENTARY INFORMATION: In an effort to develop an efficacious
treatment for human reproductive disorders this invention describes 21
progesterone analogs possessing potent antiprogestational activity with
minimal antiglucocorticoid activity. These compounds may have utility
in treating human reproductive disease and certain hormone sensitive
tumors.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective
[[Page 55887]]
exclusive license may be granted unless, within 60 days from the date
of this published Notice, NIH received written evidence and argument
that establishes that the grant of the license would not be consistent
with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
The field of use may be limited to the use of the invention for the
development of pharmaceutical compounds to treat drug human
reproductive disorders and hormone sensitive tumors.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: October 13, 1998.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 98-27961 Filed 10-16-98; 8:45 am]
BILLING CODE 4140-01-M
